The End Brain Cancer Initiative relies on generous, compassionate people, like you, who support our mission:
The EndBrainCancer Initiative | Chris Elliott Fund is dedicated to ensuring that all patients diagnosed with brain cancer, a brain tumor, or metastatic disease to the brain have equal access to advanced diagnostics, FDA-approved treatments, specialists and clinical trials. We believe that IMMEDIATE ACCESS to these options provides the patient community with the best HOPE for survival and sustained quality of life. We advocate for policy and care improvements while echoing the patient’s voice in clinical trial protocol. We partner with industry, patients, researchers, advocacy groups, medical teams, hospital networks and others to educate patients and their caregivers with a focus on next generation sequencing so they can have empowered conversations with medical teams.
Corporate matching gifts are a type of philanthropy in which companies financially match donations that their employees make to nonprofit organizations.
When you make your donation, you can now request a matching gift from your employer. Most companies usually match donations at a 1:1 ratio, but some will match at a 2:1, 3:1, or even a 4:1 ratio!
Aren't sure if your company matches employee donations? Use the tool below to find out and take the next step in DOUBLING your donation!
Donor Advised Funds (DAF) are a simple, flexible and tax-advantageous way to give to your donate to the End Brain Cancer Initiative. It's a great way to support us now and in the future!
Not only do you get the benefit of a tax deductible donation, you also have investment options that will grow your donation over time and stay tax deductible.
Benefits of Donor Advised Funds (DAF):
Easily contribute a wide range of assets
Maximize potential tax benefits
Invest your donation for tax-free growth
Simplify recordkeeping and organization
Support your legacy planning
*Ask your financial Advisor about your DAF options!
ENDBRAINCANCER INITIATIVE | CHRIS ELLIOTT FUND
Enhancing patient outcomes by expanding FDA-approved treatment modalities and fueling research in the pharma/bio/life sciences, device & diagnostic industries and by closing the existing GAP from initial diagnosis to IMMEDIATE AND EXPANDED ACCESS to specialists, researchers, advanced & innovative treatments, clinical trials and critical care with the ultimate goal of improving patient outcomes through updating and improving WHO & NCCN Guidelines and clinical practices related to Standard of Care for brain cancer patients.